GlycoEra
PrivateLast Round
Series B
May 27, 2025
Total Funding Raised
$179M
Company Overview
GlycoEra operates in Healthcare & Life Sciences and is based in Wädenswil. Its latest recorded funding round was a Series B round in May 2025.
GlycoEra is a biotechnology company that develops innovative biologics and protein degraders to treat inflammatory, autoimmune, and immune-oncology conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GlycoEra Comparables
Compare GlycoEra with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Lycia Therapeutics | 83% | |
| Avilar Therapeutics | 83% | |
| Biohaven Ltd. | 78% |
For institutional investors. Book with your work email.
GlycoEra Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 27, 2025 | ||||
| Series A Extension | Jan 5, 2024 | ||||
| Series A | Nov 5, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
GlycoEra Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Agent Capital | Series B |
| Roche Venture Fund | Series B, Series A |
| Sixty Degree Capital | Series B |
| MP Healthcare Venture Management | Series B |
| 5AM Ventures | Series B, Series A Extension, Series A |
| Catalio Capital Management | Series B |
| Roche Venture Fund | Series A Extension, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors grew 109% MoM, from 1.7K to 3.5K.
- Jan 8, 2026
Petra Duda, M.D., Ph.D. appointed as new CMO.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresSep 16, 2026
GlycoEra, Inc. appoints Andrea Matthews as chief business officer in Switzerland on Sep 16th '26, as it advances GE8820 and evaluates opportunities for its extracellular protein degradation platform.
For institutional investors. Book with your work email.
GlycoEra Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about GlycoEra's valuation, stock price, and market status.
Is GlycoEra a public or private company?
GlycoEra is a private company.
What is the current stock price of GlycoEra?
GlycoEra is a private company, so its shares have no public market price. Caplight tracks GlycoEra's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is GlycoEra worth (valuation)?
Valuation information for GlycoEra is not publicly available.
Can I buy GlycoEra stock?
GlycoEra shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was GlycoEra's last funding round?
GlycoEra's most recent funding round was Series B on May 27, 2025.
Who are the main investors in GlycoEra?
Key investors in GlycoEra include Roche Venture Fund, 5AM Ventures, Roche Venture Fund, Novo Holdings, Sofinnova Partners.
Will GlycoEra IPO soon?
No public IPO plans have been announced for GlycoEra.
How can I track GlycoEra secondary market activity?
Caplight tracks bids, offers, and trades in GlycoEra's shares on secondary markets.